Matrine induces mitochondrial apoptosis in cisplatin-resistant non-small cell lung cancer cells via suppression of β-catenin/survivin signaling

Oncology Reports

Volumn 33, Issue 5, 2015, Pages 2561-2566

  Wang, Huan Qin ^a   Jin, Jian Jun ^a   Wang, Jing ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Anticancer therapy; Drug resistance; Matrine; Mitochondrial apoptotic pathway; catenin signaling

Indexed keywords

BETA CATENIN; CASPASE 3; CASPASE 9; CISPLATIN; MATRINE; SURVIVIN; ALKALOID; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; CASPASE; INHIBITOR OF APOPTOSIS PROTEIN; QUINOLIZINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME ACTIVATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN OVEREXPRESSION; SIGNAL TRANSDUCTION; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; METABOLISM; TUMOR CELL LINE;

ALKALOIDS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; CARCINOMA, NON-SMALL-CELL LUNG; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LUNG NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; QUINOLIZINES; SIGNAL TRANSDUCTION;

EID: 84927155246     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3844     Document Type: Article

References (34)

1. Herbst RS, Heymach JV and Lippman SM: Lung cancer. N Engl J Med 359:1367-1380, 2008.
2. Howington JA, Blum MG, Chang AC, Balekian AA and Murthy SC: Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143(Suppl 5):e278S-e313S, 2013.
3. Peters S, Zimmermann S and Adjei AA: Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. Cancer Treat Rev 40:917-926, 2014.
4. Krzakowski M, Lucas C and Gridelli C: Fractionated scheme of oral vinorelbine as single-agent therapy or in combination with cisplatin concomitantly with thoracic radiotherapy in stage III non-small-cell lung cancer: dose-escalation phase I trial. Clin Lung Cancer 15:266-273, 2014.
5. Ardizzoni A, Boni L, Tiseo M, et al: Cisplatin-versus carboplatinbased chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data metaanalysis. J Natl Cancer Inst 99:847-857, 2007.
6. D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T and Shepherd FA: Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a metaanalysis of the published literature. J Clin Oncol 23:2926-2936, 2005.
7. Rosell R, Lord RV, Taron M and Reguart N: DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 38:217-227, 2002.
8. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms of cisplatin resistance. Oncogene 31:1869-1883, 2012.
9. Gao Y, Liu Z, Zhang X, He J, Pan Y, Hao F, Xie L, Li Q, Qiu X and Wang E: Inhibition of cytoplasmic GSK-3β increases cisplatin resistance through activation of Wnt/β-catenin signaling in A549/DDP cells. Cancer Lett 336:231-239, 2013.
10. Doble BW and Woodgett JR: GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116:1175-1186, 2003.
11. Orford K, Crockett C, Jensen JP, Weissman AM and Byers SW: Serine phosphorylation-regulated ubiquitination and degradation of β-catenin. J Biol Chem 272:24735-24738, 1997.
12. Cohen P and Goedert M: GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 3:479-487, 2004.
13. Kolligs FT, Bommer G and Göke B: Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. Digestion 66:131-144, 2002.
14. Dvory-Sobol H, Sagiv E, Kazanov D, Ben-Ze'ev A and Arber N: Targeting the active β-catenin pathway to treat cancer cells. Mol Cancer Ther 5:2861-2871, 2006.
15. Wei Y, Shen N, Wang Z, Yang G, Yi B, Yang N, Qiu Y and Lu J: Sorafenib sensitizes hepatocellular carcinoma cells to cisplatin via suppression of Wnt/β-catenin signaling. Mol Cell Biochem 381:139-144, 2013.
16. Huang WC, Chan CC, Wu SJ, Chen LC, Shen JJ, Kuo ML, Chen MC and Liou CJ: Matrine attenuates allergic airway inflammation and eosinophil infiltration by suppressing eotaxin and Th2 cytokine production in asthmatic mice. J Ethnopharmacol 151:470-477, 2014.
17. Yang Y, Xiu J, Zhang X, Zhang L, Yan K, Qin C and Liu J: Antiviral effect of matrine against human enterovirus 71. Molecules 17:10370-10376, 2012.
18. Liu Y, Xu Y, Ji W, Li X, Sun B, Gao Q and Su C: Anti-tumor activities of matrine and oxymatrine: literature review. Tumour Biol 35:5111-5119, 2014.
19. Niu H, Zhang Y, Wu B, Zhang Y, Jiang H and He P: Matrine induces the apoptosis of lung cancer cells through downregulation of inhibitor of apoptosis proteins and the Akt signaling pathway. Oncol Rep 32:1087-1093, 2014.
20. Li Y, Zhang ZN, Zhao HM, Tong ZC, Yang J, Wang H and Liang XJ: Matrine inhibits the invasive properties of human osteosarcoma cells by downregulating the ERK-NF-κB pathway. Anticancer Drugs 25:1035-1043, 2014.
21. Xie BS, He XX, Ai ZL and Yao SK: Involvement of β-catenin in matrine-induced autophagy and apoptosis in WB-F344 cells. Mol Med Rep 9:2547-2553, 2014.
22. Guo D, Chen NN, Zhou P, Pan B and Hou LB: Suppressive effect of matrine on cell growth and decreases beta-catenin-dependent transcriptional activity in hepatoma cell line Hep3B. Zhong Yao Cai 33:778-781, 2010 (In Chinese).
23. Jiang Z, Yin J, Fu W, Mo Y, Pan Y, Dai L, Huang H, Li S and Zhao J: miRNA 17 family regulates cisplatin-resistant and metastasis by targeting TGFbetaR2 in NSCLC. PLoS One 9:e94639, 2014.
24. He K, Xu T, Xu Y, Ring A, Kahn M and Goldkorn A: Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway. Int J Cancer 134:43-54, 2014.
25. Nagano H, Tomimaru Y, Eguchi H, Hama N, Wada H, Kawamoto K, Kobayashi S, Mori M and Doki Y: MicroRNA-29a induces resistance to gemcitabine through the Wnt/β-catenin signaling pathway in pancreatic cancer cells. Int J Oncol 43:1066-1072, 2013.
26. Shen DY, Zhang W, Zeng X and Liu CQ: Inhibition of Wnt/β-catenin signaling downregulates P-glycoprotein and reverses multi-drug resistance of cholangiocarcinoma. Cancer Sci 104:1303-1308, 2013.
27. Teng Y, Wang X, Wang Y and Ma D: Wnt/β-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem Biophys Res Commun 392:373-379, 2010.
28. Zhou H, Xu M, Gao Y, et al: Matrine induces caspase-independent program cell death in hepatocellular carcinoma through bid-mediated nuclear translocation of apoptosis inducing factor. Mol Cancer 13:59, 2014.
29. Green DR and Kroemer G: The pathophysiology of mitochondrial cell death. Science 305:626-629, 2014.
30. Zhang S, Zhang Y, Zhuang Y, Wang J, Ye J, Zhang S, Wu J, Yu K and Han Y: Matrine induces apoptosis in human acute myeloid leukemia cells via the mitochondrial pathway and Akt inactivation. PLoS One 7:e46853, 2012.
31. Cheung CH, Huang CC, Tsai FY, et al: Survivin - biology and potential as a therapeutic target in oncology. Onco Targets Ther 6:1453-1462, 2013.
32. Okamoto K, Okamoto I, Okamoto W, Tanaka K, Takezawa K, Kuwata K, Yamaguchi H, Nishio K and Nakagawa K: Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations. Cancer Res 70:10402-10410, 2010.
33. Tian H, Liu S, Zhang J, et al: Enhancement of cisplatin sensitivity in lung cancer xenografts by liposome-mediated delivery of the plasmid expressing small hairpin RNA targeting Survivin. J Biomed Nanotechnol 8:633-641, 2012.
34. Yu Q, Chen B, Zhang X, Qian W, Ye B and Zhou Y: Arsenic trioxide-enhanced, matrine-induced apoptosis in multiple myeloma cell lines. Planta Med 79:775-781, 2013.